Skip to main content

Table 8 Reported incidence of hematological adverse events in clinical trials of TKIs in NSCLC

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Drug Trial Name ORR (CR/PR) mPFS (mo) Neutropenia Lymphopenia Anemia Thrombocytopenia Reference
All grades (%) Grade 3 and 4 (%) All grades (%) Grade 3 and 4 (%) All grades (%) Grade 3 and 4 (%) All grades (%) Grade 3 and 4 (%)
Osimertinib FLAURA (NCT02296125) 80% (3%/77%) 18.9 NA 4/279 (1.4%) NA 4/279 (1.4%) 34/279 (12.2%) 3/279 (1.1%) NA 2/279 (0.7%) Soria JC (2018); Ramalingam SS (2020) [43, 44]
Osimertinib ADAURA (NCT02511106) NA NA NA 1/337 (0.3%) NA NA NA NA NA NA Wu YL (2020) [46]
Erlotinib and ramucirumab RELAY (NCT02411448) 76% (1%/75%) 19.4 25/221 (11.3%) 6/221 (2.7%) NA NA 22/221 (10%) 4/221 (1.8%) 31/221 (14%) 3/221 (1.4%) Nakagawa K (2019) [56]
Erlotinib RELAY (NCT02411448) 75% (1%/74%) 12.4 16/225 (7.1%) 2/225 (0.89%) NA NA 10/225 (4.4%) 1/225 (0.44%) 6/225 (2.7%) 0/225 (0%) Nakagawa K (2019) [56]
Gefitinib ARCHER 1050 (NCT01774721) 72% (2%/70%) 9.2 4/224 (1.8%) 1/224 (0.45%) 2/224 (0.89%) 1/224 (0.45%) 16/224 (7.1%) 5/224 (2.2%) NA NA Wu YL (2017); Mok TS (2018) [57, 58]
Afatinib LUX-Lung 6 (NCT01121393) 66.9% (1.2%/65.7%) 11 2/239 (0.84%) 1/239 (0.42%) NA NA 19/239 (7.9%) 1/239 (0.42%) 4/239 (1.7%) 0/239 (0%) Wu YL (2014) [59]
Dacomitinib ARCHER 1050 (NCT01774721) 75% (5%/70%) 14.7 5/227 (2.2%) 0/227 (0%) 2/227 (0.88%) 0/227 (0%) 22/227 (9.7%) 2/227 (0.88%) NA NA Wu YL (2017); Mok TS (2018) [57, 58]
Alectinib J-ALEX (JapicCTI-132,316) 92% (2%/89%) NA 3/103 (2.9%) 2/103 (1.9%) NA NA 6/103 (5.8%) 1/103 (0.97%) NA NA Hida T (2017) [60]
Brigatinib ALTA-1 L (NCT02737501) 71% (4%/67%) 12 2/136 (1.5%) 0/136 (0%) NA NA NA NA NA NA Camidge DR (2018) [61]
Brigatinib ALTA (NCT02094573) Arm B: 54% 12.9 NA NA NA NA NA NA NA NA Kim D (2021) [62]
Poziotinib ZENITH20 (NCT03318939) 27.8% 5.5 NA NA NA NA NA NA NA NA Ternyila D (2020) [63]
Capmatinib Geometry Mono-1 (NCT02414139) 41% (0%/41%) 5.4 NA NA NA NA NA NA NA NA Wolf J (2020) [48]
Selpercatinib LIBRETTO-001 (NCT03157128) 64% (2%/62%) 16.5 NA NA NA NA NA NA NA NA Drilon A (2020) [49]
  1. Abbreviations CR complete response, mo month, mPFS median progression free survival, NA not available, ORR overall response rate, PR partial response